Clinical trials: Panic
Panic Disorder, Mental Illness
Efficacy and Safety of HB-1 for Panic Disorder
The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo and two monotherapies, in male and female adult patients aged 18 to 65 years, inclusive, with Panic Disorder.
- Trial name
- NCT06483789
- Testing
- HB-1, Telmisartan Only Product in Oral Dose Form, Verapamil Only Product in Oral Dose Form
- Where
- 19 sites in Australia
- Volunteers
- 170 people
- Sponsor
- HB BioTech, LLC
Panic Disorder
Xenon Inhalation for Treatment of Panic Disorder
This study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with panic disorder.
- Trial name
- NCT04432155
- Testing
- Xenon
- Volunteers
- 200 people
- Sponsor
- Nobilis Therapeutics Inc.
Panic Disorder
Safety and Efficacy of HB-1 for Panic Disorder
The purpose of this study is to determine the safety and efficacy of potential new treatment called "HB-1" versus placebo in male and female adult patients aged 18 to 60 years, inclusive, with panic disorder.
- Trial name
- NCT05071430
- Testing
- HB-01
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- HB BioTech, LLC
Healthy
A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms
The main objective of this trial is to investigate the pharmacodynamic effects of a single dose of BI 1358894 on CCK-4- induced anxiogenic/ panic-like symptoms using the PSS in preselected CCK-4 sensitive healthy volunteers.
- Trial name
- NCT03904576
- Testing
- BI 1358894
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder (MDD, Anxiety Disorder, Generalized
Serotonin Variants & Gut Microbiota in Mental Health
This observational pilot study investigates whether a broad panel of genetic variants relevant to the serotonin pathway (including serotonergic system, methylation cycle, intestinal barrier integrity, and inflammatory response…
- Conditions
- Major Depressive Disorder (MDD, Anxiety Disorder, Generalized, Stress Disorders, Post-Traumatic, Panic Disorder
- Trial name
- NCT07634458
- Testing
- SNP Genotyping and Gut Metagenomics
- Volunteers
- 30 people
- Sponsor
- Neurobiologix
Panic Disorder
A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
To evaluate the efficacy and safety of sertraline compared to paroxetine in patients with panic disorder.
- Trial name
- NCT00677352
- Testing
- sertraline, Paroxetine
- Where
- 22 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Panic Disorder
Study Evaluating Venlafaxine ER in Adults With Panic Disorder
The primary objective of this study is to determine the efficacy, safety, and tolerability of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in the treatment of adult outpatients with…
- Trial name
- NCT00038896
- Testing
- Venlafaxine ER
- Volunteers
- 343 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Panic Disorder
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
The purpose of this trial is to measure the efficacy, safety, and tolerability of darigabat (25 milligrams [mg] twice daily [BID]) compared with placebo in participants with panic disorder.
- Trial name
- NCT05941442
- Testing
- Darigabat
- Where
- 31 sites in United States
- Volunteers
- 80 people
- Sponsor
- AbbVie
Panic Disorder, Depression
Drug Use Investigation of Jzoloft.
The objective of this surveillance is to collect information about 1) adverse drug reactions not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in this surveillance, and 3)…
- Trial name
- NCT00605865
- Testing
- Sertraline hydrochloride
- Volunteers
- 2,272 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Panic Disorder
A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics of alprazolam extended release (XR) for the treatment of adolescents with panic disorder
- Trial name
- NCT00635531
- Testing
- alprazolam XR
- Where
- 18 sites in United States
- Volunteers
- 16 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Panic Disorder
ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment
This study is designed to investigate if 600 mg ELB139 given orally t.i.d. to patients suffering from panic disorder is effective in reducing anxiety evoked by inhalation of 35% CO2 measured by a visual analogue scale after the…
- Trial name
- NCT00322803
- Testing
- ELB139
- Where
- 3 sites in Germany, Netherlands
- Volunteers
- 24 people
- Sponsor
- elbion AG
Panic Disorder
A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks
The purpose of this study is to assess the long-term safety and tolerability of alprazolam extended release (XR) in adolescents with panic disorder, with or without agoraphobia, or in anxiety disorder with panic attacks.
- Trial name
- NCT00634790
- Testing
- alprazolam XR
- Where
- 47 sites in United States
- Volunteers
- 49 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Anxiety, Fear
A Randomized Controlled Test of the Effects of CHI-554 on Fear.
This is a randomized, double-blind, placebo-controlled phase 2b clinical trial examining the effects of CHI-554 (CBD) on Fear (F-01)
- Conditions
- Anxiety, Fear, Panic
- Trial name
- NCT04577612
- Testing
- CHI-554
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Canopy Growth Corporation
Panic Disorders
Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder
The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.
- Trial name
- NCT00195598
- Testing
- VENLAFAXINE, Paroxetine
- Where
- 4 sites in Brazil
- Volunteers
- 70 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Generalized Anxiety Disorder, Panic Disorder
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
An 8-week, open-label trial in 848 subjects at 212 sites to compare time to response in symptoms of anxiety in subjects treated with Niravam™ and a newly prescribed Selective Serotonin Reuptake Inhibitor (SSRI)or Serotonin and…
- Trial name
- NCT00266409
- Testing
- Niravam, SSRI/SNRI
- Where
- United States
- Volunteers
- 418 people
- Sponsor
- UCB Pharma
Panic Disorder
Study Evaluating Venlafaxine ER in Patients With Panic Disorder
The primary objective is to determine the efficacy, safety, and tolerability of venlafaxine extended release (ER) capsules in the treatment of outpatients with panic disorder (PD) in comparison to those of placebo.
- Trial name
- NCT00044772
- Testing
- Venlafaxine ER
- Volunteers
- 653 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Post-traumatic Stress Disorder (PTSD)
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
- Trial name
- NCT05189977
- Testing
- Propranolol, Prazosin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression, Panic Disorder
Special Investigation Of Long Term Use Of Sertraline.
Special investigation of long term use of sertraline, 52 Week Observation, Long-Term Safety. The objective of this "Special investigation" is to collect information about 1) adverse drug reactions not expected from the LPD…
- Trial name
- NCT00605813
- Testing
- Sertraline hydrochloride
- Volunteers
- 542 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Panic Disorder
A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder
The purpose of this study is to evaluate the long-term (6-month) efficacy, safety, and tolerability of alprazolam XR in adolescents with panic disorder.
- Trial name
- NCT00635076
- Testing
- alprazolam XR
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Panic Disorder
Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)
The purpose of this study is to evaluate the effectiveness of Org 25935 vs. placebo given in combination with cognitive-behavioral therapy (CBT) to reduce the symptoms of panic disorder.
- Trial name
- NCT00725725
- Testing
- Cognitive-behavioral therapy, Org 25935
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC